title: A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.
abstract: Toxic epidermal necrolysis and Stevens-Johnson syndrome are severe skin reactions, usually to drugs, associated with a widespread destruction of the epidermis. Widespread purpuric macules and epidermal detachment of less than 10% of the body surface is indicative of Stevens-Johnson syndrome, whereas epidermal detachment between 10% and 30% is called Stevens-Johnson-toxic epidermal necrolysis overlap. Epidermal detachment involving more than 30% of the total body surface is designated as toxic epidermal necrolysis. These generalized reactions are known to occur in association with various drugs. Treatment is primarily supportive care, and there are no specific therapy regimens. Therapeutic modalities such as corticosteroids, cyclosporin, thalidomide, cyclophosphamide, and plasmapheresis, usually based on a symptomatic approach, have been tried in single patients or in small series. Intravenous immunoglobulin has recently been shown to provide rapid improvement in all three of these skin reactions. We report a 2-year-old girl who developed Stevens-Johnson syndrome-toxic epidermal necrolysis overlap after receiving ampicillin-sulbactam for an upper respiratory tract infection. She was treated successfully with a 4-day course of intravenous immunoglobulin.
authors.affiliation: Department of Dermatology, Gülhane Military Medical Academy, School of Medicine, Etlik, Ankara, Turkey. earca@gata.edu.tr
authors.forename: Ercan
authors.initials: E
authors.lastname: Arca
authors.forename: Osman
authors.initials: O
authors.lastname: Köse
authors.forename: A Hakan
authors.initials: AH
authors.lastname: Erbil
authors.forename: Mustafa
authors.initials: M
authors.lastname: Nişanci
authors.forename: Ahmet
authors.initials: A
authors.lastname: Akar
authors.forename: Ali Riza
authors.initials: AR
authors.lastname: Gür
mesh_terms: D000667:Ampicillin / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013262:Stevens-Johnson Syndrome / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D013407:Sulbactam / Q000009:adverse effects
chemical_list: D000900:Anti-Bacterial Agents; D016756:Immunoglobulins, Intravenous; D000667:Ampicillin; D013407:Sulbactam